News
EPRX
6.70
+0.60%
0.04
Eupraxia Deepens Investment in EP-104GI as New Data Strengthen EoE Prospects
TipRanks · 18h ago
Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline
Benzinga · 18h ago
Eupraxia Pharmaceuticals reports Q2 results
Seeking Alpha · 18h ago
Weekly Report: what happened at EPRX last week (0803-0807)?
Weekly Report · 2d ago
Eupraxia Pharmaceuticals files $300M mixed securities shelf
TipRanks · 6d ago
David Martin Reiterates Buy on Eupraxia Pharmaceuticals, Citing Strong KOL Support for EP-104GI’s Commercialization Potential
TipRanks · 08/03 13:16
Weekly Report: what happened at EPRX last week (0727-0731)?
Weekly Report · 08/03 09:37
Stifel Nicolaus Reaffirms Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 07/31 15:46
Sam Slutsky Reiterates Buy Rating on EP-104GI Developer, Maintains $16 Price Target
TipRanks · 07/31 15:46
Analyst Reiterates Buy on EPRX, Keeps EP-104GI Upside Reflected in Unchanged $11 Price Target
TipRanks · 07/31 11:05
Eupraxia Pharmaceuticals: Buy Rating Backed by EP-104GI’s Seamless Fit Into GI Practice and Strong Commercial Outlook
TipRanks · 07/31 08:35
Weekly Report: what happened at EPRX last week (0720-0724)?
Weekly Report · 07/27 09:39
Buy Rating Reaffirmed on EPRX as EP-104GI Catalyst Nears and $16 Price Target Remains Unchanged
TipRanks · 07/21 22:02
Cantor Fitzgerald Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
TipRanks · 07/20 13:15
Weekly Report: what happened at EPRX last week (0713-0717)?
Weekly Report · 07/20 09:37
Eupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down
NASDAQ · 07/14 06:03
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone
TipRanks · 07/13 20:58
Eupraxia chief scientific and operating officer Amanda Malone steps down
TipRanks · 07/13 20:15
Weekly Report: what happened at EPRX last week (0706-0710)?
Weekly Report · 07/13 09:38
Stifel Nicolaus Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 07/10 11:35
More
Webull provides a variety of real-time EPRX stock news. You can receive the latest news about Eupraxia Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.